bioAffinity CEO to Present at H.C. Wainwright Conference, Highlighting CyPath® Lung Progress
Event summary
- bioAffinity CEO Maria Zannes to present corporate update at H.C. Wainwright conference on September 14-16, 2026.
- Company to discuss strategic milestones, commercial adoption of CyPath® Lung diagnostic test.
- Live and archived webcast of presentation available starting September 11, 2026.
- CyPath® Lung marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services.
The big picture
bioAffinity's participation in the H.C. Wainwright conference underscores its push to validate CyPath® Lung's commercial viability. The focus on strategic milestones and investor meetings suggests a strategic pivot toward scaling its diagnostic platform. The broader industry trend of noninvasive diagnostics for early cancer detection positions bioAffinity as a key player in a rapidly evolving market.
What we're watching
- Commercial Momentum
- How bioAffinity will leverage the conference to accelerate CyPath® Lung adoption among institutional investors.
- Strategic Milestones
- Whether the upcoming milestones will position bioAffinity for potential partnerships or acquisitions.
- Regulatory Dynamics
- The pace at which bioAffinity can navigate CLIA regulations to expand its diagnostic offerings.
Related topics